VELBAN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELBAN (vinblastine sulfate) is a vinca alkaloid small-molecule injectable chemotherapy agent approved in 1965 for various malignancies. It works by disrupting microtubule formation, arresting cancer cells in metaphase. The product is now in late-stage lifecycle with loss of exclusivity approaching.
LOE Approaching
As a legacy product approaching LOE with moderate competitive pressure (30%), commercial teams are likely focused on retention and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VELBAN offers limited career growth opportunities with zero linked job openings currently available. Working on this legacy product is best suited for professionals seeking stability and deep expertise in cost management, payer relations, and oncology market dynamics rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on VELBAN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.